CA2276276A1 - Cancer treatment drug - Google Patents
Cancer treatment drug Download PDFInfo
- Publication number
- CA2276276A1 CA2276276A1 CA002276276A CA2276276A CA2276276A1 CA 2276276 A1 CA2276276 A1 CA 2276276A1 CA 002276276 A CA002276276 A CA 002276276A CA 2276276 A CA2276276 A CA 2276276A CA 2276276 A1 CA2276276 A1 CA 2276276A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- cancer
- kotshyi
- boss
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a cancer treatment drug containing two biological plant active ingredients having a cytotoxic action and carcinolytic properties, namely extracts from the plants Peganum Harmala L. and Drakocephalum Kotshyi Boss.
Description
., . CA 02276276 1999-06-28 PHARMACEUTICAL RESEARCH CENTER
Drug for cancer therapy The invention concerns a drug for cancer therapy, which is founded on a biological basis.
Cancer is an illness in which body cells grow uncontrolledly. Various therapies are known for preventing or at least confining cell growth of that kind. One of the therapies which is most frequently applied at the present time is so-called chemotherapy which suffers from serious side effects without however resulting in sustained successes.
Tests with biological cancer therapies alone have also hitherto not afforded long-lasting successes because it was also hitherto not possible for the cancer cells which are formed in the human body to be effectively destroyed with those therapies.
The object of the present invention is to provide a drug or pharmaceutical preparation which has anti-cancer or cytostatic effects) by means of which cancer cells can be effectively destroyed or at least curbed.
In accordance with the invention that object is attained by a drug having the features of claim 1.
Advantageous configurations and embodiments of the invention are the subject-matter of the appendant claims.
The anti-cancer agent according to the invention is a drug which contains two vegetable substances with cytotoxic action and which can be administered orally and/or rectally and/or parenterally.
This combination anti-cancer preparation preferably contains extracts of two plants, more specifically Peganum harmala L. and Dracocephalum Kotshyi Boss which contain substances having a cancer-inhibiting action.
Plants of that kind are indigenous to Iran.
Phytochemical investigations of those plants confirm inter alia the presence of active substance such as alkaloids, flavonoids, tannin, saponins, steroids, proteins, lipids, carbohydrates, essential oils.
minerals, amino acids and so forth.
The constituents or ingredients of the plant extracts to be used in accordance with the invention are firstly prepared in the form of alcoholic and aqueous extracts or solutions. Granules are produced from the mixture which is formed therefrom. The granules and extracts which are obtained in that way are processed to form tablets or other medicinal forms of presentation in order to administer them to patients.
The drug according to the invention has inter alia cytotoxic, anti phlogistic, anti-inflammatory, analgesic, anti-bacterial and anti-viral actions.
The biological anti-cancer agent according to the invention acts as a mitosis inhibitor and intervenes with an inhibiting effect in the mitosis phase in cell division of cancer-affected cells.
The biological anti-cancer agent according to the invention combines after administration with the deoxyribonucleic acid (DNA) chain and thereby prevents the formation of ribonucleic acid (RNA). In that way it interferes with the amino acids of the cells which are affected by cancer and thus prevents cancer cell growth.
The molecular building structure of the biological anti-cancer agent or preparati on accordi ng to the i nventi on i s such that the agent functi ons as a physiological and body-compatible agent in the body.
It has been found that the drug or preparation according to the invention gives rise to positive therapy effects in relation to various cancer tumours, for example mammary carcinoma, carcinomas of the gastro intestinal tract, brain tumours and the like.
A particular advantage of the invention is that the positive therapy effect can be achieved in relation to cancer cells, without side effects of any consequence.
In particular the drug or preparation according to the invention, upon administration, does rot have any adverse side effects on the blood count and the natural blood components.
Drug for cancer therapy The invention concerns a drug for cancer therapy, which is founded on a biological basis.
Cancer is an illness in which body cells grow uncontrolledly. Various therapies are known for preventing or at least confining cell growth of that kind. One of the therapies which is most frequently applied at the present time is so-called chemotherapy which suffers from serious side effects without however resulting in sustained successes.
Tests with biological cancer therapies alone have also hitherto not afforded long-lasting successes because it was also hitherto not possible for the cancer cells which are formed in the human body to be effectively destroyed with those therapies.
The object of the present invention is to provide a drug or pharmaceutical preparation which has anti-cancer or cytostatic effects) by means of which cancer cells can be effectively destroyed or at least curbed.
In accordance with the invention that object is attained by a drug having the features of claim 1.
Advantageous configurations and embodiments of the invention are the subject-matter of the appendant claims.
The anti-cancer agent according to the invention is a drug which contains two vegetable substances with cytotoxic action and which can be administered orally and/or rectally and/or parenterally.
This combination anti-cancer preparation preferably contains extracts of two plants, more specifically Peganum harmala L. and Dracocephalum Kotshyi Boss which contain substances having a cancer-inhibiting action.
Plants of that kind are indigenous to Iran.
Phytochemical investigations of those plants confirm inter alia the presence of active substance such as alkaloids, flavonoids, tannin, saponins, steroids, proteins, lipids, carbohydrates, essential oils.
minerals, amino acids and so forth.
The constituents or ingredients of the plant extracts to be used in accordance with the invention are firstly prepared in the form of alcoholic and aqueous extracts or solutions. Granules are produced from the mixture which is formed therefrom. The granules and extracts which are obtained in that way are processed to form tablets or other medicinal forms of presentation in order to administer them to patients.
The drug according to the invention has inter alia cytotoxic, anti phlogistic, anti-inflammatory, analgesic, anti-bacterial and anti-viral actions.
The biological anti-cancer agent according to the invention acts as a mitosis inhibitor and intervenes with an inhibiting effect in the mitosis phase in cell division of cancer-affected cells.
The biological anti-cancer agent according to the invention combines after administration with the deoxyribonucleic acid (DNA) chain and thereby prevents the formation of ribonucleic acid (RNA). In that way it interferes with the amino acids of the cells which are affected by cancer and thus prevents cancer cell growth.
The molecular building structure of the biological anti-cancer agent or preparati on accordi ng to the i nventi on i s such that the agent functi ons as a physiological and body-compatible agent in the body.
It has been found that the drug or preparation according to the invention gives rise to positive therapy effects in relation to various cancer tumours, for example mammary carcinoma, carcinomas of the gastro intestinal tract, brain tumours and the like.
A particular advantage of the invention is that the positive therapy effect can be achieved in relation to cancer cells, without side effects of any consequence.
In particular the drug or preparation according to the invention, upon administration, does rot have any adverse side effects on the blood count and the natural blood components.
2 The drug or preparation according to the invention can be administered as a mono- and/or combination therapy preparation with other biosubstances and anti-tumour agents which have been produced on a biological and/or conventional basis.
The drug or preparation according to the invention has a synergistic effect in combination with oral oxygen therapy, whereby the effect of the anti-cancer action is increased.
It has been found that the agent or preparation according to the invention has a relaxant and relief effect. in particular in regard to smooth musculatures.
The drug or preparation according to the invention has immunostimulating and immunomodulating actions. Those properties have been investigated and confirmed in relation to animals whose immune systems were crippled by dimethylbenzanthracene (DMBA) as a carcinogenic and immunosuppressive agent. In those animals, after treatment with the biological anti-cancer agent according to the invention, immunostimulation and immunomodulation were noted and documented. Those positive effects on the immune system of a human being have also been demonstrated.
It was also possible to demonstrate a reduction in tumour markers in the case of cancer patients treated with the drug or preparation according to the invention.
Pharmacodynamical investigations with the drug or preparation according to the invention showed a lethal dose (LDso) of 657.5 mg/kg bodyweight in the case of investigated mice.
Pharmacodynamical comparative investigations with other anti-tumour agents such as Vincristin. Vinblastin and Chlorambucil showed that the drug or preparation according to the invention has optimum compatibility while the previously known cancer-treatment agents give rise to serious side effects which did not occur when using the drug according to the invention.
The cancer-inhibiting action of the drug or preparation according to the invention was confirmed and documented by various cell investigations and effects on cancer cells in humans and apes.
The drug or preparation according to the invention has a synergistic effect in combination with oral oxygen therapy, whereby the effect of the anti-cancer action is increased.
It has been found that the agent or preparation according to the invention has a relaxant and relief effect. in particular in regard to smooth musculatures.
The drug or preparation according to the invention has immunostimulating and immunomodulating actions. Those properties have been investigated and confirmed in relation to animals whose immune systems were crippled by dimethylbenzanthracene (DMBA) as a carcinogenic and immunosuppressive agent. In those animals, after treatment with the biological anti-cancer agent according to the invention, immunostimulation and immunomodulation were noted and documented. Those positive effects on the immune system of a human being have also been demonstrated.
It was also possible to demonstrate a reduction in tumour markers in the case of cancer patients treated with the drug or preparation according to the invention.
Pharmacodynamical investigations with the drug or preparation according to the invention showed a lethal dose (LDso) of 657.5 mg/kg bodyweight in the case of investigated mice.
Pharmacodynamical comparative investigations with other anti-tumour agents such as Vincristin. Vinblastin and Chlorambucil showed that the drug or preparation according to the invention has optimum compatibility while the previously known cancer-treatment agents give rise to serious side effects which did not occur when using the drug according to the invention.
The cancer-inhibiting action of the drug or preparation according to the invention was confirmed and documented by various cell investigations and effects on cancer cells in humans and apes.
3 The extract obtained and produced in accordance with the invention from two specific plants and its fractions were allowed to act on cancer cells and control cells. The progression of that effect was monitored through an electron microscope. Ultra-structural damage to the cancer cells was found. in comparison with healthy control cells.
In cl i ni cal studi es , when usi ng the agent accordi ng to the i nventi on i n rel ati on to cancer pati ents , there was found i n part total remi ssi on as well as an increase in life expectancy and an improvement in quality of life.
The invention is further described hereinafter by reference to a practical embodiment of a cancer-inhibiting drug set out in table form.
Constituent mg/tablet Peganum harmala L. 142.7 23.8 Dracocephalum K.B. 19.6 3.3 Sugar powder 15,7 2.6 Calcium carbonate 43.6 7.3 Polyvinyl pyrrolidone (PVP)12.5 2.0 Starch 166.5 27.g Lactose 156.0 26.0 Carboxymethylcellulose (CMC)10.0 1.6 Microcrystalline cellulose 24.0 4.0 (MCC>
Aerosyl 9.4 1.6 600.0 mg 100.0 _ 4
In cl i ni cal studi es , when usi ng the agent accordi ng to the i nventi on i n rel ati on to cancer pati ents , there was found i n part total remi ssi on as well as an increase in life expectancy and an improvement in quality of life.
The invention is further described hereinafter by reference to a practical embodiment of a cancer-inhibiting drug set out in table form.
Constituent mg/tablet Peganum harmala L. 142.7 23.8 Dracocephalum K.B. 19.6 3.3 Sugar powder 15,7 2.6 Calcium carbonate 43.6 7.3 Polyvinyl pyrrolidone (PVP)12.5 2.0 Starch 166.5 27.g Lactose 156.0 26.0 Carboxymethylcellulose (CMC)10.0 1.6 Microcrystalline cellulose 24.0 4.0 (MCC>
Aerosyl 9.4 1.6 600.0 mg 100.0 _ 4
Claims (4)
1. A drug for cancer therapy characterised in that it contains two biological vegetable active substances with cytotoxic action which thus have cancer cell-destroying properties.
2. A drug as set forth in claim 1 characterised in that as active substances having cancer cell-destroying properties it contains extracts from the plants Peganum Harmala L. and Dracocephalum Kotshyi Boss.
3. A drug as set forth in claim 1 or claim 2 characterised in that it contains about 24% Peganum Harmala L. and between about 3 and 4%
Dracocephalum Kotshyi Boss, with the balance fillers.
Dracocephalum Kotshyi Boss, with the balance fillers.
4. A drug as set forth in claim 3 characterised in that it contains 23.8% Peganum Harmala L. and 3.3% Dracocephalum Kotshyi Boss.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1997/006155 WO1999024048A1 (en) | 1997-11-06 | 1997-11-06 | Cancer treatment drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2276276A1 true CA2276276A1 (en) | 1999-05-20 |
Family
ID=8166782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002276276A Abandoned CA2276276A1 (en) | 1997-11-06 | 1997-11-06 | Cancer treatment drug |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0951291A1 (en) |
| JP (1) | JP2001514671A (en) |
| CA (1) | CA2276276A1 (en) |
| WO (1) | WO1999024048A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| WO2012027481A1 (en) * | 2010-08-24 | 2012-03-01 | Gtx, Inc. | Compounds for treatment of cancer |
| CN102286085B (en) * | 2011-07-25 | 2014-06-11 | 新疆大学 | Peganum harmala lipid transfer protein and preparation method and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1034135A (en) * | 1987-10-27 | 1989-07-26 | 新疆医学院第二附属医院 | The preparation method of peganum harmala seed extract |
| CN1047528C (en) * | 1993-11-18 | 1999-12-22 | 王世渝 | Pharmaceutics of common peganum herb and its preparation |
-
1997
- 1997-11-06 CA CA002276276A patent/CA2276276A1/en not_active Abandoned
- 1997-11-06 WO PCT/EP1997/006155 patent/WO1999024048A1/en not_active Application Discontinuation
- 1997-11-06 EP EP97948892A patent/EP0951291A1/en not_active Withdrawn
- 1997-11-06 JP JP52524399A patent/JP2001514671A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0951291A1 (en) | 1999-10-27 |
| WO1999024048A1 (en) | 1999-05-20 |
| JP2001514671A (en) | 2001-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ijaz et al. | Nigella sativa (Prophetic Medicine): A Review. | |
| Namba | Maitake D-fraction: healing and preventive potential for cancer | |
| US6395311B2 (en) | Multicomponent biological vehicle | |
| US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
| JPH0344048B2 (en) | ||
| Chekka et al. | Momordica charantia: A natural medicinal plant | |
| US20090142419A1 (en) | Anti-inflammatory extract and agent and method for the production thereof | |
| CA2700338C (en) | Anti-aids, anti-tumor, immune system stimulating herbal composition and production method | |
| CA2276276A1 (en) | Cancer treatment drug | |
| AU2016307998B2 (en) | Composition comprising tannins | |
| Rimple et al. | Poly pharmacological effects of green blood therapy: An update | |
| CN113209065B (en) | Use of alkaloid compounds for the production of products for the prevention and/or treatment of heart damage | |
| RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| Tantra et al. | Alpha-mangostin as potent osteogenesis and anti-inflammation bioactive material-literature review | |
| US20050182037A1 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
| CN102008470B (en) | Compound preparation and use thereof for preventing and treating noise induced hearing damage | |
| KR102028383B1 (en) | Composition for preventing or treating hearing loss | |
| CN111728985B (en) | A composition containing oviductus Ranae as main ingredient and its application | |
| WO2003097076A1 (en) | Herbal formulations against adenocarcinoma of the prostate | |
| CA2407429C (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
| KR102007096B1 (en) | Composition for preventing or treating hearing loss comprising Viscum ovalifolium extracts | |
| JPH06199696A (en) | Carcinostatic anticancer agent | |
| BESBES et al. | Study of the cytotoxicity and therapeutic virtues of some aromatic and medicinal plants used in traditional Algerian medicine | |
| EP4355347A1 (en) | Composition for the prevention and/or treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |